Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04912076
Other study ID # 2018-001486-17
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 17, 2018
Est. completion date March 22, 2019

Study information

Verified date December 2023
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this clinical phase I single centre, randomized, double-blind, placebo-controlled study with open comparator is to investigate tolerability and safety as well as the immunological effects of BM41 in comparison to placebo (double blind) and to a standard subcutaneous immunotherapy Alutard SQ (open) in birch allergic patients.


Description:

Please see original article.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date March 22, 2019
Est. primary completion date March 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Signed informed consent 2. Age =18 = 65 years 3. Moderate to severe birch-pollen-induced allergic rhinitis/rhinoconjunctivitis of at least 2 years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Appendix 1, see the manual of procedures) with or without concomitant mild to moderate persistent asthma 4. Forced expiratory volume (FEV1) >70% for patients with a history of asthma, FEV1>70% or peak flow (PEF) >80% for patients without a history of asthma 5. A positive skin prick test (SPT) (mean wheal diameter = 3mm compared to negative control and negative control should be negative) for birch pollen assessed within 1 year before randomization 6. Specific IgE against birch pollen extract = 0.7 kU/L and against Bet v 1 = 0.35 kU/L as determined by ImmunoCAP Exclusion Criteria: 1. Chronic asthma with an FEV1<70 % of predicted value. 2. History of allergen immunotherapy (AIT) (subcutaneous (SCIT) or sublingual (SLIT)) with birch pollen or tree pollen mix including birch pollen within the past 5 years 3. Ongoing AIT (SCIT or SLIT) with any allergen(s) during the study period 4. Vaccination within one week before or during the treatment phase. 5. Immunosuppressive or biological medication (e.g. IL-5, anti-IgE therapy) within the last six months prior to inclusion and up to end of trial (EoT). 6. Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs. 7. Uncontrolled asthma or other active respiratory diseases. 8. Active malignancies or any malignant disease during the previous 5 years. 9. Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases, or haematological disorders. 10. Renal insufficiency 11. Active inflammation or infection of the target organs (nose, eyes or lower airways) at the start of the study. 12. Diseases with a contraindication for the use of adrenaline (e.g. hyperthyroidism, glaucoma). 13. Use of systemic steroids within 4 weeks before start of the study and during the study. 14. Treatment with systemic and local ß-blockers. 15. Known allergy towards constituents of the vaccine 16. Pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age (adequate contraceptive measures will be intrauterine device or hormonal contraception (birth control pill, implant, transdermal patch, vaginal ring or depot injection). It is also accepted, if the female patient is permanently sterile or infertile, if her sole partner is permanently sterile, or if they use both condom and diaphragm, The definition of sterile or infertile is surgically sterilized (vasectomy/bilateral salpingectomy, hysterectomy and/or bilateral ovariectomy) or post menopause defined as a non-menstrual period of at least 12 months before inclusion in the study. 17. Alcohol, drug or medication abuse within the past year. 18. Any clinically significant abnormal laboratory parameter at screening. 19. Lack of cooperation or compliance. 20. Any physical or mental condition that precludes administration of SCIT, compliance or participation in a clinical trial. 21. Patients who are students or employees of the institution or 1st grade relatives or partners of the investigators 22. Participation in a clinical trial within 3 months prior to the current trial.

Study Design


Intervention

Drug:
BM41
Subcutaneous injection of increasing doses of BM41
Other:
Placebo
Subcutaneous injections of placebo containing aluminium hydroxide.
Drug:
ALK Alutard SQ Betula verrucosa
Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.

Locations

Country Name City State
Denmark Odense Research Center for Anaphylaxis, Odense University Hospital Odense

Sponsors (5)

Lead Sponsor Collaborator
Odense University Hospital Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Biomay AG, European Commission, University of Salzburg

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events with emphasis on allergic reactions. Safety/tolerability of subcutaneous treatment with BM41 compared to placebo (double-blind) and to a conventional standardized birch pollen extract in patients with birch pollen allergy Safety/tolerability of subcutaneous treatment with BM41 compared to placebo (double-blind) and to a conventional standardized birch pollen extract.
Number and character of all adverse events will be evaluated.
Through study completion, an average of 4 months
Secondary Changes in serum immunoglobulin E (IgE), immunoglobulin G (IgG) and immunoglobulin G4 (IgG4) levels. Evaluation of immunological responses during subcutaneous allergen immunotherapy (SCIT) with BM41 compared to placebo and to a conventional, standardized and registered birch pollen extract (Alutard SQ).The evaluation will be done by monitoring changes in serum immunoglobulin E (IgE), immunoglobulin G (IgG) and immunoglobulin G4 (IgG4) levels against recombinant Bet v 1 (rBet v 1), BM41 and birch pollen extract. Serum will also be used in a so-called IgE facilitated allergen-binding assay (FAB) and in a rat basophilic leukemia cell (RBL)-based histamine release test, to monitor the functional blocking antibody capacity of induced IgG/IgG4 antibodies. Day 7, 42 and 126
Secondary Epigenetic changes induced by BM41 and Alutard compared to placebo DNA will be isolated from a blood sample. Day 7, 42 and 126
Secondary Changes in wheal sizes upon titrated skin prick test with BM41. Evaluation of hypo-allergenicity before first exposure but also during repeated exposure to BM41. Day 7, 42 and 112
Secondary Changes in the capacity to block IgE facilitated allergen binding and histamine release. It will be evaluated in an IgE facilitated allergen binding (FAB) assay and in a rat basophilic leukemia cell (RBL)-based histamine release test. Day 7, 42 and 126
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT03682965 - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Phase 2
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01966224 - A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects Phase 1
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Completed NCT01438827 - Avanz Phleum Pratense Maintenance Dose Phase 2/Phase 3
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2
Completed NCT02437786 - Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Phase 4
Completed NCT00985296 - Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC) N/A
Completed NCT01740284 - A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine Phase 3
Completed NCT03365648 - Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics N/A
Completed NCT05455749 - Effect of holoBLG on Cat Allergic Patients N/A
Completed NCT01707069 - A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Phase 1
Completed NCT01567306 - Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense Phase 2
Completed NCT01466465 - Vitamin D and Grass Pollen Specific Immunotherapy Phase 2
Completed NCT01490411 - Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis Phase 2
Completed NCT00777374 - Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration Phase 2
Active, not recruiting NCT04502966 - Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction Phase 2